Sign in
CompletedNo phase

SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)

Key facts

Who runs it
The Geneva Foundation
Where
Fort Sam Houston, United StatesSee the site
Trial code
Status
Completed
People taking part
300 people enrolled
Started
15 May 2023
Ended
30 Mar 2026
Type of study
Observational, 2 groups
Treatments tested
  • imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
Record updated
15 July 2026

Who can take part

Age
18 years to 89 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Asymptomatic and symptomatic individuals 18 years and older
  • Receiving standard COVID-19, Flu, and/or RSV screening and testing at BAMC
  • Do not have to be diagnosed with SARS-CoV-19 (COVID-19), Flu, and/or RSV but only be screened
  • English Speaking

Who cannot take part

  • Any individual under age of 18
  • Anyone unable to comply (or be assisted) with study procedures
  • Anyone not able to provide temperature thermal scan, and/or 3-minute vibroacoustic scan

Where in United States

  • Brooke Army Medical CenterFort Sam Houston, United States

About the trial

What the trial wants to find out

The goal of this observational study is to evaluate new non-invasive passive surveillance technologies, Level 42 AI imPulse™ Una and TOR devices for the detection of COVID-19, Flu, and/or RSV in asymptomatic and symptomatic individuals over age of 18 undergoing COVID-19, Flu, and/or RSV screening and testing at BAMC Ft Sam Houston, TX; with and without COVID-19, Flu, and/or RSV.

Read full original descriptionShow less

The hypotheses are:

(H1) The imPulseTM Una and the imPulseTM TOR e-stethoscopes have at least a similar discriminative and detection ability among symptomatic and asymptomatic COVID-19 carrier versus those not infected compared to gold standard RT-PCR. We will operationalize and deploy both the imPulseTM Una and imPulseTM TOR e-stethoscope into DoD use-cases and compare their usability between the devices.

(H2) Identify if the imPulseTM Una and the imPulseTM TOR e-stethoscopes have at least a similar discriminative and detection ability among symptomatic and asymptomatic Respiratory Syncytial Virus (RSV), Influenza and Long COVID carriers versus those not infected compared to gold standard Rapid RSV and Flu Antigen Tests, or RT-PCR and molecular assays. We will operationalize and deploy both the imPulseTM Una and imPulseTM TOR e-stethoscope into DoD use-cases and compare their captured traces in the early identification of disease/illness analyzed by the devices built in algorithms.

(H3) In the mid to long-term, this approach will also be explored as a diagnostic system to explore pursue the physical (structural and mechanical) properties of cells and tissues that maintain normal cell behavior (motility, growth, apoptosis), and the critical importance of the ability of cells to sense and respond to mechanical stresses, which will be operationally critical for assessment of both traumatic and unconventional exposures in austere environments.

Participants will:

* Be consented; * Be screened for COVID-19, Flu, and/or RSV symptoms according to BAMC's current screening procedures; * Have study data collected; * Complete a symptoms questionnaire; * imPulseTM Una and TOR e-stethoscopes examination will be conducted; * Participants will be compensated for completing all study requirements. (Active-Duty personnel must complete the study procedures while off-duty in order to receive compensation.)

The 2 groups in the trial

  • COVID-19, Flu, and/or RSV positive patients

    Participants screened with known COVID-19, Flu, and/or RSV positive test results obtained within 48hrs of recruitment.

    Treatment: imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope

  • COVID-19, Flu, and/or RSV negative patients

    Participants screened with known COVID-19, Flu, and/or RSV negative test results obtained within 48hrs of recruitment.

    Treatment: imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
Record updated
15 July 2026